UVA1 irradiation attenuates collagen production via Ficz/AhR/MAPK signaling activation in scleroderma

Area of Science:

• Dermatology
• Immunology
• Molecular Biology

Background:

• Scleroderma is an autoimmune disease causing progressive skin fibrosis with significant patient burden.
• Current treatments for scleroderma are limited due to its unclear cause.
• The Aryl hydrocarbon receptor (AhR) pathway is implicated in systemic sclerosis (SSc) pathogenesis.

Purpose of the Study:

• To investigate if ultraviolet A1 (UVA1) phototherapy's anti-fibrotic effects in scleroderma are mediated by the Ficz/AhR/MAPK signaling pathway.
• To explore the role of AhR activation in treating fibrotic lesions in both systemic sclerosis (SSc) and localized scleroderma (LS).

Main Methods:

• Analysis of fibrotic lesions in SSc and LS patients treated with UVA1 phototherapy.
• Investigating the activation of the Ficz/AhR/MAPK signaling pathway in response to UVA1 treatment.

Main Results:

• UVA1 phototherapy demonstrates anti-fibrotic effects in scleroderma lesions.
• The study provides the first evidence linking the AhR pathway to the anti-fibrotic mechanism of UVA1 phototherapy.
• This research highlights the AhR pathway's role in the fibrotic mechanisms of systemic scleroderma.

Conclusions:

• UVA1 phototherapy's anti-fibrotic action in scleroderma may be partly due to Ficz/AhR/MAPK signaling activation.
• Ficz and other AhR agonists show potential as alternative anti-fibrotic agents for scleroderma, possibly replacing UVA1 phototherapy.